Cargando…

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Detalles Bibliográficos
Autores principales:	Page, David B, Naidoo, Jarushka, Momtaz, Parisa, Bogatch, Kita, Kuk, Deborah, Panageas, Katherine, Yuan, Jianda, Wolchok, Jedd D, Postow, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288411/ http://dx.doi.org/10.1186/2051-1426-2-S3-P117

Ejemplares similares

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Caregivers Clinic at Memorial Sloan Kettering Cancer Center
por: Applebaum, Allison
Publicado: (2021)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
por: Ku, Geoffrey Y, et al.
Publicado: (2010)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center
por: Lidsky, Michael E., et al.
Publicado: (2018)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
por: Postow, Michael A., et al.
Publicado: (2015)

The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer
por: Wan, Mingyu, et al.
Publicado: (2023)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Integrative Cancer Care in a US Academic Cancer Centre: The Memorial Sloan–Kettering Experience
por: Deng, G.
Publicado: (2008)

Memorial Sloan-Kettering Cancer Center: Two Decades of Experience with Ductal Carcinoma In Situ of the Breast
por: Choi, Daniel Xavier, et al.
Publicado: (2012)

Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
por: Bazzi, Wassim M., et al.
Publicado: (2014)

Antiproliferative Effects of the Methanolic Petiole Extract of Eichhornia crassipes Against Sloan Kettering Melanoma 5 Cell Line: An In Vitro Study
por: P, Noufal K, et al.
Publicado: (2022)

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
por: Soff, Gerald A., et al.
Publicado: (2019)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
por: Momtaz, Parisa, et al.
Publicado: (2017)

Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification
por: Choong, Caroline Victoria, et al.
Publicado: (2011)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
por: Oses, Gabriela, et al.
Publicado: (2023)

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
por: Lapointe, Réjean, et al.
Publicado: (2015)

Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi)
por: Page, David B, et al.
Publicado: (2014)

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
por: Bamias, Aristotelis, et al.
Publicado: (2010)

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
por: Puzanov, Igor
Publicado: (2015)

The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria
por: Tamada, Satoshi, et al.
Publicado: (2018)

The association between Memorial Sloan Kettering Frailty Index with 30-day survival among patients aged ≥ 75 with cancer and COVID-19
por: Kim, Soo Jung, et al.
Publicado: (2022)

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
por: Friedman, Claire F, et al.
Publicado: (2022)

Thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis (FAP): Memorial Sloan-Kettering Cancer Center (MSKCC) registry experience
por: Markowitz, Arnold J, et al.
Publicado: (2011)

Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center
por: Romesser, Paul B., et al.
Publicado: (2020)

External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer
por: Milonas, Daimantas, et al.
Publicado: (2020)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Validation of the Memorial Sloan-Kettering Cancer Center Nomogram to Predict Disease-Specific Survival after R0 Resection in a Chinese Gastric Cancer Population
por: Chen, Donglai, et al.
Publicado: (2013)

Validation of the Memorial Sloan Kettering Cancer Center nomogram for predicting non-sentinel lymph node metastasis in sentinel lymph node-positive breast-cancer patients
por: Bi, Xiang, et al.
Publicado: (2015)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Evaluation of Memorial Sloan‐Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma
por: Jahr, Guro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qfiojca1oq8kb4cduq594udgnj